Delores Schendel, Medigene CEO (Vimeo via website)

Medi­gene cuts TCR-T ther­a­py in piv­ot to fo­cus on sol­id tu­mors

It’s been sev­er­al months since Medi­gene AG laid out plans to de­vote it­self to sol­id tu­mors. In keep­ing with that promise, the Ger­man biotech said …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.